Efficacy and Safety of High-Flow Nasal Cannula During Transcatheter Closure Procedures

November 9, 2026 updated by: Ke-Yun, Chao, Fu Jen Catholic University

Efficacy and Safety of High-Flow Nasal Cannula During Transcatheter Closure Procedures for Congenital Heart Disease

This study aims to evaluate the efficacy and safety of high-flow nasal cannula oxygen therapy, compared with standard nasal cannula oxygen therapy, as respiratory support during transcatheter closure procedures for congenital heart disease under non-intubated deep sedation.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Transcatheter closure is a standard treatment for selected congenital heart diseases and is often performed under deep sedation with transesophageal echocardiographic guidance. During non-intubated sedation, oxygen desaturation may occur due to airway collapse, respiratory depression, supine positioning, or limited cardiopulmonary reserve. Standard nasal cannula oxygen may be insufficient in high-risk patients, whereas HFNC provides heated, humidified high-flow oxygen, stable FiO2, dead-space washout, and mild positive airway pressure to improve oxygenation and airway stability. This study will enroll pediatric and adult patients undergoing transcatheter closure for congenital heart disease. Participants will be stratified by age and/or clinical risk and randomized to receive either HFNC or standard nasal cannula oxygen therapy. This study is expected to clarify whether HFNC can reduce intra-procedural oxygen desaturation, improve oxygenation stability, decrease emergency airway interventions, and maintain hemodynamic safety during deep sedation. The findings may support standardized respiratory support protocols in cardiac catheterization laboratories and provide evidence for individualized peri-procedural care in pediatric and adult congenital heart disease patients.

Study Type

Interventional

Enrollment (Estimated)

150

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • New Taipei City, Taiwan, 24352
        • Fu Jen Catholic University Hospital, Fu Jen Catholic University
        • Principal Investigator:
          • Ke-Yun Chao, PhD
        • Contact:
      • Yunlin, Taiwan
        • National Taiwan University Hospital Yunlin Branch
        • Contact:
        • Principal Investigator:
          • Hīng-Ka Lîm, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 months and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Diagnosed with a simple congenital heart defect, including an atrial septal defect, ventricular septal defect, patent ductus arteriosus, or patent foramen ovale, and scheduled for an elective transcatheter closure procedure.
  • American Society of Anesthesiologists physical status classification I-III.
  • Written informed consent.

Exclusion Criteria:

  • Complex congenital heart disease.
  • Severe anatomical abnormalities of the upper airway.
  • Preprocedural severe cyanosis or hypoxemia, defined as an oxygen saturation below 90% while room air.
  • A contraindication to high-flow nasal cannula, as determined by the physician.
  • A skin condition over the chest that prevents placement of electrodes for noninvasive cardiac output monitoring.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: High-flow nasal cannula group

Receive high-flow nasal cannula during transcatheter closure procedures under deep sedation

Heated, humidified high-flow oxygen will be delivered through a nasal cannula.

Active Comparator: Conventional nasal cannula oxygen therapy

Receive conventional nasal cannula oxygen therapy during transcatheter closure procedures under deep sedation

Oxygen will be delivered through a nasal cannula.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of hypoxemia
Time Frame: From initiation of the assigned oxygen therapy to completion of transcatheter closure procedure

Defined as at least one episode of peripheral oxygen saturation below 90% lasting at least 10 seconds

From initiation of the assigned oxygen therapy to completion of transcatheter closure procedure

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Ke-Yun Chao, PhD, Fu Jen Catholic University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

July 31, 2027

Study Completion (Estimated)

July 31, 2027

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 9, 2026

First Posted (Actual)

November 16, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • FJUH115607

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.